A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice

MicrobiologyOpen

Volumn 4, Issue 3, 2015, Pages 465-474

  Aiba, Yuji ^a,b   Nakano, Yasuhiro ^a,b   Koga, Yasuhiro ^a   Takahashi, Kenji ^b   Komatsu, Yasuhiko ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sumikin Kansai Industries Co   (Japan)

Author keywords

Helicobacter pylori; Lactobacillus johnsonii; Gastroesophageal reflux disease; Lactic acid bacteria; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; GASTRIN; PROTON PUMP INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CELL PH; CELL SURVIVAL; ESCHERICHIA COLI O157; GASTRIN RELEASE; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; INTESTINE FLORA; JAPANESE (PEOPLE); LACTOBACILLUS JOHNSONII; MALE; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; STOMACH ACID SECRETION; STOMACH JUICE; VOLUNTEER; ANIMAL; ANTIBIOSIS; BLOOD; DISEASE MODEL; HELICOBACTER INFECTION; ISOLATION AND PURIFICATION; LACTOBACILLUS; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); STOMACH ACID;

CLOSTRIDIUM DIFFICILE; ESCHERICHIA COLI O157; HELICOBACTER PYLORI; LACTOBACILLUS; LACTOBACILLUS JOHNSONII; MUS; SALMONELLA TYPHIMURIUM;

ANIMALS; ANTIBIOSIS; DISEASE MODELS, ANIMAL; GASTRIC ACID; GASTRINS; GASTROINTESTINAL MICROBIOME; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOBACILLUS; MICE; PROTON PUMP INHIBITORS;

EID: 84931005669     PISSN: None     EISSN: 20458827     Source Type: Journal    
DOI: 10.1002/mbo3.252     Document Type: Article

References (27)

1. Aiba, Y., N. Suzuki, A. M. Kabir, A. Takagi, and Y. Koga. 1998. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gastroenterol. 93:2097-2101.
2. Bader, J., A. Albin, and U. Stahl. 2012. Spore-forming bacteria and their utilisation as probiotics. Benef. Microbes 3:67-75.
3. Charteris, W. P., P. M. Kelly, L. Morelli, and J. K. Collins. 1998. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J. Appl. Microbiol. 84:759-768.
4. Cotter, P. D., and C. Hill. 2003. Surviving the acid test: responses of gram-positive bacteria to low pH. Microbiol. Mol. Biol. Rev. 67:429-453.
5. De Vuyst, L., P. Vincent, E. Makras, F. Leroy, and B. Pot. 2010. Peptide extracts from cultures of certain lactobacilli inhibit Helicobacter pylori. Probiotics Antimicrob. Proteins 2:26-36.
6. Felley, C. P., I. Corthesy-Theulaz, J. L. Rivero, P. Sipponen, M. Kaufmann, P. Bauerfeind, et al. 2001. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur. J. Gastroenterol. Hepatol. 13:25-29.
7. Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogiovanni, N. Bucci, et al. 2008. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13:127-134.
8. Francavilla, R., L. Polimeno, A. Demichina, G. Maurogiovanni, B. Principi, G. Scaccianoce, et al. 2014. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J. Clin. Gastroenterol. 48:407-413.
9. Franz, C. M., M. E. Stiles, K. H. Schleifer, and W. H. Holzapfel. 2003. Enterococci in foods-a conundrum for food safety. Int. J. Food Microbiol. 88:105-122.
10. Fujimura, S., S. Kato, M. Oda, M. Miyahara, Y. Ito, K. Kimura, et al. 2006. Detection of Lactobacillus gasseri OLL2716 strain administered with yogurt drink in gastric mucus layer in humans. Lett. Appl. Microbiol. 43:578-581.
11. Gilliland, S. E., L. Morelli, and G. Reid. 2001. Health and nutrition properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a joint FAO/WHO expert consultation on evaluation of health and nutrirional properties of probiotics in food including powder milk with live lactic acid bacteria.
12. Kabir, A. M., Y. Aiba, A. Takagi, S. Kamiya, T. Miwa, and Y. Koga. 1997. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 41:49-55.
13. Kailasapathy, K., and J. Chin. 2000. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol. Cell Biol. 78:80-88.
14. Kinoshita, Y., and S. Ishihara. 2000. Mechanism of gastric mucosal proliferation induced by gastrin. J. Gastroenterol. Hepatol. 15(Suppl.):D7-D11.
15. Malfertheiner, P., J. Dent, L. Zeijlon, P. Sipponen, S. J. Veldhuyzen Van Zanten, C. F. Burman, et al. 2002. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Aliment. Pharmacol. Ther. 16:1431-1442.
16. Malfertheiner, P., F. Megraud, C. O'morain, F. Bazzoli, E. El-Omar, D. Graham, et al. 2007. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56:772-781.
17. McColl, K. E., A. Dickson, A. El-Nujumi, E. El-Omar, and A. Kelman. 2000. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am. J. Gastroenterol. 95:101-105.
18. Mercenier, A., S. Pavan, and B. Pot. 2003. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr. Pharm. Des. 9:175-191.
19. Metchnikoff, E. 1908. Lactic acid as inhibiting intestinal putrefaction. Pp. 160-183 in P. C. Mitchell, ed. The prolongation of life: optimistic studies. G. P. Putnam's Sons, London.
20. Michetti, P., G. Dorta, P. H. Wiesel, D. Brassart, E. Verdu, M. Herranz, et al. 1999. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 60:203-209.
21. Midolo, P. D., J. R. Lambert, R. Hull, F. Luo, and M. L. Grayson. 1995. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J. Appl. Bacteriol. 79:475-479.
22. Prasad, J., H. Gill, J. Smart, and P. K. Gopal. 1998. Selection and characterisatino of Lactobacillus and Bifidobacterium strains for use as probiotics. Int. Dairy J. 8:993-1002.
23. Sakamoto, I., M. Igarashi, K. Kimura, A. Takagi, T. Miwa, and Y. Koga. 2001. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrob. Chemother. 47:709-710.
24. Takahashi, H., Y. Nakano, T. Matsuoka, N. Kumaki, Y. Asami, and Y. Koga. 2011. Role of indigenous lactobacilli in gastrin-mediated acid production in the mouse stomach. Appl. Environ. Microbiol. 77:6964-6971.
25. Takeda, K., O. Takeuchi, and S. Akira. 2002. Recognition of lipopeptides by Toll-like receptors. J. Endotoxin Res. 8:459-463.
26. Williams, J. G., A. R. Kubelik, K. J. Livak, J. A. Rafalski, and S. V. Tingey. 1990. DNA polymorphisms amplified by arbitrary primers are useful as genetic markers. Nucleic Acids Res. 18:6531-6535.
27. Xie, T., X. Cui, H. Zheng, D. Chen, L. He, and B. Jiang. 2013. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 25:1195-1205.